Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Pipeline Review, H1 2016

Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Pipeline Review, H1 2016
Published Jun 30, 2016
62 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Pipeline Review, H1 2016, provides in depth analysis on Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted pipeline therapeutics.

The report provides comprehensive information on the Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37)
- The report reviews Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted therapeutics and enlists all their major and minor projects
- The report assesses Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive adva

  
Source:
Document ID
GMDHC0195TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Overview71
Therapeutics Development83
  Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Products under Development by Stage of Development81
  Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Products under Development by Therapy Area91
  Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Products under Development by Indication101
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Products under Development by Companies132
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Products under Development by Universities/Institutes152
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Therapeutics Assessment176
  Assessment by Monotherapy/Combination Products171
  Assessment by Mechanism of Action181
  Assessment by Route of Administration192
  Assessment by Molecule Type212
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Companies Involved in Therapeutics Development234
  Cantex Pharmaceuticals, Inc.231
  Chiesi Farmaceutici SpA241
  Kamada Ltd.251
  Polyphor Ltd.261
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Drug Profiles2715
  alpha-1 proteinase inhibitor (human) Drug Profile275
  ANV-201 Drug Profile321
  Brevenal Drug Profile331
  CX-01 Drug Profile342
  POL-6014 Drug Profile362
  Polysaccharides to Inhibit P-Selectin and HLE for Age-Related Macular Degeneration Drug Profile381
  Small Molecule 1 to Inhibit Neutrophil Elastase for Immunology, Oncology and Respiratory Disorders Drug Profile391
  Small Molecule 2 to Inhibit Neutrophil Elastase for Immunology, Oncology and Respiratory Disorders Drug Profile401
  Small Molecules to Inhibit Neutrophil Elastase for Respiratory Diseases Drug Profile411
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Dormant Projects423
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Discontinued Products451
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Featured News &Press Releases4615
  Jun 15, 2016: Shire and Kamada announce FDA approval of expanded label for self-infusion of Glassia for the treatment of emphysema due to severe AAT deficiency461
  May 25, 2016: Kamadas Alpha-1 Antitrypsin Now Available to Treat Graft-Versus-Host Disease on myTomorrows Early Access Platform471
  Apr 06, 2016: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection472
  Mar 28, 2016: Kamada Submits Marketing Authorization Application with the European Medicines Agency for its Proprietary Inhaled Alpha-1 Antitrypsin to Treat Alpha-1 Antitrypsin Deficiency492
  Mar 02, 2016: New Patent Issued to Cantex Pharmaceuticals for Its Lead Product Candidate in the Treatment of Thrombocytopenia and Neutropenia511
  Jan 06, 2016: Kamada Reports Further Positive Interim Data from Phase 1/2 Study of its Alpha-1 Antitrypsin to Treat Graft Versus Host Disease511
  Dec 02, 2015: Kamada Provides Update on Alpha-1 Antitrypsin Development in Newly Diagnosed Type 1 Diabetes521
  Sep 01, 2015: Polyphor extends clinical development portfolio by advancing its inhaled elastase inhibitor POL6014 for lung diseases to Phase I531
  Jul 06, 2015: Kamada Announces Publication in Pediatric Diabetes541
  Jun 22, 2015: Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection551
  Jun 01, 2015: Cantex Pharmaceuticals Announces Poster Presentation at ASCO 2015 Indicating Potential Efficacy of CX-01561
  May 18, 2015: Cantex Pharmaceuticals Announces Efficacy and Safety Data from Study of CX-01 in AML to be Presented at 2015 ASCO Annual Meeting561
  May 06, 2015: Kamada to Present Key Results from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin During the American Thoracic Society 2015 International Conference571
  Apr 01, 2015: Kamada Receives Allowance for Key Canadian Patent for Large Scale Production and Use of Proprietary Alpha-1 Proteinase Inhibitor581
  Mar 23, 2015: Kamada Awarded European Orphan Drug Designation for Its Alpha-1 Antitrypsin to Treat Graft-versus-Host Disease592
Appendix612
  Methodology611
  Coverage611
  Secondary Research611
  Primary Research611
  Expert Panel Validation611
  Contact Us611
  Disclaimer621

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Neutrophil-Elastase-Human-Leukocyte-Elastase-or-Elastase-2-or-EC-3-4-21-37-Pipeline-Review-H1-2016-2088-16092>
  
APA:
Global Markets Direct - Market Research. (2016). Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Neutrophil-Elastase-Human-Leukocyte-Elastase-or-Elastase-2-or-EC-3-4-21-37-Pipeline-Review-H1-2016-2088-16092>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.